CLOS
ASND icon

Compagnie Lombard Odier SCmA’s Ascendis Pharma A/S ASND Stock Holding History

Compagnie Lombard Odier SCmA’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-224
Closed -$38.7K – 445
2025
Q2 		$38.7K Buy
+224
New +$36.5K ﹤0.01% 342

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Compagnie Lombard Odier SCmA's ASND Position: Q3 2025 in Review

Compagnie Lombard Odier SCmA sold out of Ascendis Pharma A/S (ASND) in Q3 2025, closing a stake of 224 shares — an estimated $38.7K sold.

Compagnie Lombard Odier SCmA first reported a position in ASND in Q2 2025 and held it in 1 quarter. The position peaked at $38.7K in Q2 2025. 279 funds tracked by Wall St. Rank hold ASND as of Q3 2025.

  • Compagnie Lombard Odier SCmA reported no remaining Ascendis Pharma A/S position as of Q3 2025 after selling out during the quarter.
  • Compagnie Lombard Odier SCmA sold 224 Ascendis Pharma A/S shares in Q3 2025, an estimated $38.7K.
  • Compagnie Lombard Odier SCmA first reported a position in Ascendis Pharma A/S in Q2 2025 and held it in 1 quarter.
  • Compagnie Lombard Odier SCmA's Ascendis Pharma A/S position peaked at $38.7K in Q2 2025.
  • 279 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q3 2025.

Based on Compagnie Lombard Odier SCmA's 13F filing for Q3 2025, filed 6 Nov 2025.